ClinicalTrials.gg
CompletedNCT04838405Updated Oct 20, 2025

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of CT-388 and Placebo in Diabetes, sponsored by Carmot Therapeutics, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Diabetes Mellitus by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Hoffmann-La Roche.

Enrollment
7th of 10
129 · median 180
Started
2021
with 1 other
Phase 1
3 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 11th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 12 studies in Diabetes Mellitus by Hoffmann-La Roche is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetes Mellitus by Hoffmann-La Roche as a file.
02

Study summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females
  • 18-65 years old, inclusive
  • 27.0-40.0, inclusive
  • Stable body weight for 2 months

Exclusion criteria

Exclusion Criteria:

  • Significant medical history
  • Uncontrolled hypertension
  • History of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    CT-388

    SC dose of CT-388

    Drug: CT-388

  • Placebo comparator
    Placebo

    SC dose of placebo matching CT-388 dose

    Drug: Placebo

  • Experimental
    CT-388 Optional

    SC dose of CT-388

    Drug: CT-388

  • Experimental
    CT-388 MD

    SC dose of CT-388

    Drug: CT-388

Interventions

  • DrugCT-388

    Synthetic Peptide

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events as assessed by self-report

    Safety and tolerability

    Time frame: Baseline up to 24 weeks

Secondary outcomes

  1. Area under the concentration versus time curve (AUC)

    PK AUC

    Time frame: Baseline up to 24 weeks

  2. Maximum observed drug concentration (Cmax)

    PK Cmax

    Time frame: Baseline up to 24 weeks

  3. Elimination half-life

    PK t1/2

    Time frame: Baseline up to 24 weeks

  4. Change in mean body weight

    PD body weight

    Time frame: Baseline up to 24 weeks

  5. Change in mean glucose levels

    PD glucose

    Time frame: Baseline up to 24 weeks

  6. Change in mean insulin levels

    PD insulin

    Time frame: Baseline up to 24 weeks

07

Study locations

2 sites
  • Carmot Clinical Research Unit 101
    Perth, Western Australia 6009, Australia
  • Carmot Clinical Research Unit 105
    Monterrey, Nuevo León 66260, Mexico
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2024, 37 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 37 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2021
First posted
Apr 9, 2021
StartActual
Apr 29, 2021
Primary completionActual
Jun 18, 2024
CompletionActual
Aug 2, 2024
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04838405
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Apr 29, 2021
Primary completion
Jun 18, 2024
Completion
Aug 2, 2024
Last update
Oct 20, 2025

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enicepatide

Start the discussion